Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

NCT02622074 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Nab-paclitaxel
DRUG: Anthracycline (doxorubicin)
DRUG: Cyclophosphamide
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Merck Sharp & Dohme LLC